Literature DB >> 3731522

Susceptibility to murine experimental autoallergic myasthenia gravis: the role of antibody specificity.

A L Marzo, M J Garlepp, M Schon-Hegrad, R L Dawkins.   

Abstract

To examine the differing susceptibility of C57BL/6J and C3H/HeJ mice to experimental autoallergic myasthenia gravis (EAMG), we have compared the pathogenicity of sera from the two strains. Mice were immunized with acetylcholine receptor from T. californica and muscle weakness assessed as the time mice were capable of running on an exercise drum following the administration of a sub-lethal dose of D-tubocurarine. 16 of 20 C57BL/6J and only 4 of 19 C3H/HeJ mice developed muscle weakness. However, anti-AChR antibody titres were similar in both strains. The effect of transfer of pooled immune sera from each strain to naive recipients was therefore compared. Transfer of pooled C57BL/6J sera to naive C3H/HeJ and C57BL/6J mice produced significant muscle weakness (P less than 0.001 & P less than 0.001 respectively). Transfer of pooled C3H/HeJ sera did not produce statistically significant muscle weakness in either strain. It is concluded that differences in disease susceptibility result from differences in antibody specificities of the major antibody populations, rather than differences in total antibody amounts or other factors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3731522      PMCID: PMC1542142     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  11 in total

1.  Strain differences in the autoimmune response of mice to acetylcholine receptors.

Authors:  S Fuchs; D Nevo; R Tarrab-Hazdai; I Yaar
Journal:  Nature       Date:  1976-09-23       Impact factor: 49.962

2.  Major histocompatibility complex-linked control of the murine immune response to myelin basic protein.

Authors:  R B Fritz; M J Skeen; C H Chou; M Garcia; I K Egorov
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

3.  Purification and molecular properties of the acetylcholine receptor from Torpedo electroplax.

Authors:  M E Eldefrawi; A T Eldefrawi
Journal:  Arch Biochem Biophys       Date:  1973-11       Impact factor: 4.013

Review 4.  Autoimmune response to acetylcholine receptors in myasthenia gravis and its animal model.

Authors:  J Lindstrom
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

Review 5.  Immunology of acetylcholine receptors in relation to myasthenia gravis.

Authors:  A Vincent
Journal:  Physiol Rev       Date:  1980-07       Impact factor: 37.312

6.  The diagnostic significance of autoantibodies to the acetylcholine receptor.

Authors:  M J Garlepp; P H Kay; R L Dawkins
Journal:  J Neuroimmunol       Date:  1982-12       Impact factor: 3.478

7.  Factors affecting the susceptibility of different strains of mice to experimental myasthenia gravis.

Authors:  P W Berman; J Patrick; S Heinemann; F G Klier; J H Steinbach
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

8.  Autoimmunity in ocular and generalised myasthenia gravis.

Authors:  M J Garlepp; R L Dawkins; F T Christiansen; J Lawton; G Luciani; J McLeod; J Bradley; G Genkins; C S Teng
Journal:  J Neuroimmunol       Date:  1981-09       Impact factor: 3.478

9.  Purification of anti-acetylcholine receptor antibody from patients with myasthenia gravis.

Authors:  B Lang; A Vincent; J Newsom-Davis
Journal:  J Immunol Methods       Date:  1982       Impact factor: 2.303

10.  Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental myasthenia gravis.

Authors:  P W Berman; J Patrick
Journal:  J Exp Med       Date:  1980-09-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

2.  Characterization of anti-acetylcholine receptor (AChR) antibodies from mice differing in susceptibility for experimental autoimmune myasthenia gravis (EAMG).

Authors:  Y M Graus; P J van Breda Vriesman; M H de Baets
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.